Breast Cancer-Related Lymphedema More Common Among Black Women
A prospective study sought to determine the significance of race on the risk of developing lymphedema and disease severity in women with breast cancer.
Breast Cancer
Monitoring ESR1 Mutations May Optimize Treatment in Metastatic Breast Cancer
Monitoring bESR1mut enabled optimization of the endocrine therapy used with a CDK4/6 inhibitor.
Trastuzumab Deruxtecan Improved PFS Across HER2+ Breast Cancer Subgroups
Researchers presented updated findings from the DESTINY-Breast03 trial.
Outcomes in Inflammatory Breast Cancer Improved With Modern Treatment
An analysis evaluated outcomes for patients with breast cancer who were treated with a modern approach compared with a historical standard approach.
Genomic-Based Targeted Therapy Improved PFS for Certain Metastatic Breast Cancers
The researchers found that targeted therapies matched to genomic alterations in ESCAT tier I/II significantly improved progression-free survival.
Final Analysis of PALLAS Shows No Benefit With Palbociclib Plus Endocrine Therapy in Early Breast Cancer
Palbociclib added to adjuvant endocrine therapy failed to improve iDFS.
Increasing Marker Clip Placement During Ultrasound-Guided Breast Biopsy
The delay in clip placement was associated with significant anxiety among the patients who were interviewed.
Elacestrant Improved PFS in Metastatic Breast Cancer Progressing on CDK4/6 Therapy
Elacestrant showed a statistically significant and clinically meaningful progression-free survival improvement compared with standard of care.
Recurrence Risk Reduced With AI vs Tamoxifen in Premenopausal ER+ Breast Cancer
This meta-analysis was conducted on data from 4 clinical trials including more than 7000 women with ER+ breast cancer.
KEYNOTE-355 Identifies PD-L1 Expression Cutoff for Pembrolizumab Benefit in mTNBC
A subgroup analysis of the KEYNOTE-355 trial sought to determine which patients with metastatic TNBC would benefit from treatment with pembrolizumab and chemotherapy.
